TABLE 3

Comparison of changes between vitamin E–and placebo-treated patients

Vitamin EPlaceboP
Systolic blood pressure (mmHg)
    6 months1.27 ± 17.6−2.76 ± 12.00.04
    12 months12.1 ± 18.42.1 ± 18.80.05
HbA1c (%)
    6 months0.1 (−0.3 to 0.9)−0.1 (−0.5 to 0.2)0.04*
    12 months0.0 (−0.3 to 0.7)0.0 (−0.5 to 0.4)0.53*
FMD
    6 months0.0 (−0.65 to 1.24)0.132 (−0.58 to 1.42)0.91*
    12 months−0.48 (−2.77 to 1.49)0.71 (−0.19 to 2.48)0.04*
NID
    6 months−0.28 (−1.67 to 1.56)−0.44 (−0.86 to 0.31)0.84*
    12 months−1.3 (−5.65 to 0.04)0.00 (−0.66 to 0.48)0.02*
Cholesterol (mg/dl)
    6 months0.0 (−9.6 to 16.8)−6.5 (−28.5 to 10.5)0.04*
    12 months0.5 (−14.0 to 21.5)−14 (−26.0 to 5.0)0.03*
LDL cholesterol (mg/dl)
    6 months8.76 ± 22.4−3.0 ± 28.80.08
    12 months5.9 ± 22.4−1.65 ± 25.80.22
Ach
    6 months−6 (−15 to 13)11.3 (0–33)0.02*
    12 months−2 (−21 to 23)−6 (−23 to 15)0.71*
Endothelin (pg/ml)
    6 months0.1 (−0.1 to 0.2)−0.1 (−0.2 to 0.0)0.01*
    12 months0 (−0.1 to 0.2)−0.1 (−0.2 to 0.1)0.23*
tPA (μg/ml)
    6 months0.25 (−0.58 to 1.72)−0.40 (−2.3 to 0.5)0.04*
    12 months0.4 (−1.0 to 2.3)−0.3 (−1.2 to 0.8)0.17*
CRP at 12 months (μg/ml)−0.045 (−0.17 to 0.01)0.02 (−0.02 to 0.11)0.05*
  • Data are means ± SD or median (25th−75th percentile). Data for FMD, NID, and Ach represent percent of increase over baseline. Because of multiple comparisons, P < 0.025 was used for significance level.

  • *

    * Kruskal-Wallis test for significant difference was used for these nonnormally distributed data.